Literature DB >> 8534665

Towards cytokine insight in sight.

J T Rosenbaum1.   

Abstract

Mesh：

Substances：

Year:  1995        PMID： 8534665      PMCID： PMC505308          DOI： 10.1136/bjo.79.11.970

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN： 0007-1161            Impact factor:   4.638


× No keyword cloud information.
  14 in total

1.  Treatment with recombinant human tumor necrosis factor-alpha protects rats against the lethality, hypotension, and hypothermia of gram-negative sepsis.

Authors:  H R Alexander; B C Sheppard; J C Jensen; H N Langstein; C M Buresh; D Venzon; E C Walker; D L Fraker; M C Stovroff; J A Norton
Journal:  J Clin Invest       Date:  1991-07       Impact factor: 14.808

Review 2.  Cytokines: the good, the bad, and the unknown.

Authors:  J T Rosenbaum
Journal:  Invest Ophthalmol Vis Sci       Date:  1993-07       Impact factor: 4.799

Review 3.  Interferon beta-1b.

Authors:  D E Goodkin
Journal:  Lancet       Date:  1994-10-15       Impact factor: 79.321

4.  Repeated therapy with monoclonal antibody to tumour necrosis factor alpha (cA2) in patients with rheumatoid arthritis.

Authors:  M J Elliott; R N Maini; M Feldmann; A Long-Fox; P Charles; H Bijl; J N Woody
Journal:  Lancet       Date:  1994-10-22       Impact factor: 79.321

5.  Processing of tumour necrosis factor-alpha precursor by metalloproteinases.

Authors:  A J Gearing; P Beckett; M Christodoulou; M Churchill; J Clements; A H Davidson; A H Drummond; W A Galloway; R Gilbert; J L Gordon
Journal:  Nature       Date:  1994-08-18       Impact factor: 49.962

6.  A protein kinase involved in the regulation of inflammatory cytokine biosynthesis.

Authors:  J C Lee; J T Laydon; P C McDonnell; T F Gallagher; S Kumar; D Green; D McNulty; M J Blumenthal; J R Heys; S W Landvatter; J E Strickler; M M McLaughlin; I R Siemens; S M Fisher; G P Livi; J R White; J L Adams; P R Young
Journal:  Nature       Date:  1994 Dec 22-29       Impact factor: 49.962

7.  Activity of an interleukin 1 receptor antagonist in rabbit models of uveitis.

Authors:  J T Rosenbaum; R S Boney
Journal:  Arch Ophthalmol       Date:  1992-04

8.  Induction of vascular endothelial growth factor gene expression by interleukin-1 beta in rat aortic smooth muscle cells.

Authors:  J Li; M A Perrella; J C Tsai; S F Yet; C M Hsieh; M Yoshizumi; C Patterson; W O Endege; F Zhou; M E Lee
Journal:  J Biol Chem       Date:  1995-01-06       Impact factor: 5.157

9.  Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders.

Authors:  L P Aiello; R L Avery; P G Arrigg; B A Keyt; H D Jampel; S T Shah; L R Pasquale; H Thieme; M A Iwamoto; J E Park
Journal:  N Engl J Med       Date:  1994-12-01       Impact factor: 91.245

10.  Effect of tumor necrosis factor alpha on insulin-dependent diabetes mellitus in NOD mice. I. The early development of autoimmunity and the diabetogenic process.

Authors:  X D Yang; R Tisch; S M Singer; Z A Cao; R S Liblau; R D Schreiber; H O McDevitt
Journal:  J Exp Med       Date:  1994-09-01       Impact factor: 14.307
View more
  3 in total

Review 1.  The emerging roles of topical non-steroidal anti-inflammatory agents in ophthalmology.

Authors:  P Koay
Journal:  Br J Ophthalmol       Date:  1996-05       Impact factor: 4.638

Review 2.  Drug-induced uveitis. Incidence, prevention and treatment.

Authors:  F W Fraunfelder; J T Rosenbaum
Journal:  Drug Saf       Date:  1997-09       Impact factor: 5.606

3.  Treatment of uveitis with recombinant human interleukin-13.

Authors:  F G Roberge; M D de Smet; J Benichou; M F Kriete; J Raber; J Hakimi
Journal:  Br J Ophthalmol       Date:  1998-10       Impact factor: 4.638
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.